HOME / CONTACT US
繁體版 / 简体版
  • ABOUT COMPANY
    • History
    • Team
    • Collabration
    • Nanchou Plant
    • Expanded Access Program
  • SCIENCE
    • Pipeline & Therapeutic area
    • ON101
    • OB318
    • FB825
    • FB704A
    • FB918
    • SNS01
    • Technology
  • INVESTOR
    • Corporate Governance
    • Financials
    • Shareholders’ Meeting
    • Corporate Presentation
    • Investor FAQs
  • NEWS
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
  • CSR
    • Human rights policy
  • CAREERS
    • Careers
    • Join us
  • ABOUT COMPANY
    • History
    • Team
    • Collabration
    • Nanchou Plant
    • Expanded Access Program
  • SCIENCE
    • Pipeline & Therapeutic area
    • ON101
    • OB318
    • FB825
    • FB704A
    • FB918
    • SNS01
    • Technology
  • INVESTOR
    • Corporate Governance
      • Governance Structure Shareholding Structure Board of Directors Audit Committee Compensation Committee Internal Audit Major Internal Policies
    • Financials
      • Financial Report / Financial Statements Stock Quotes
    • Shareholders’ Meeting
      • Annual Report Meeting Minutes / Meeting Agenda Meeting Notice
    • Corporate Presentation
      • Events and Presentations
    • Investor FAQs
      • CONTACT US FAQs(category)
    • ABOUT COMPANY
      • History Team Collabration Nanchou Plant Expanded Access Program
    • SCIENCE
      • Pipeline & Therapeutic area ON101 OB318 FB825 FB704A FB918 SNS01 Technology
    • CSR
      • Human rights policy
    • Careers
      • Careers Join us
  • NEWS
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
  • CAREERS
    • Careers
    • Join us
  • CONTACT US
  • 繁體版
  • 简体版
 
 
NEWS
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017

NEWS

 

Title Date
MSCI adds Oneness Biotech to Global Standard Indexes 2020-11-11
The latest release of MSCI Taiwan Small Cap Index 2020-10-30
Oneness Biotech Listed in MSCI Taiwan Small Cap Index 2020-06-30
Successful topline Phase 3 data of ON101 new drug 2020-06-15
Oneness Biotech will proceed to unblind Phase 3 data of ON101 MRCT (protocol#ON101CLCT02) according to TFDA notification letter# 1096013906 2020-05-26
Oneness Biotech receives upfront payment of US$14.48M from LEO Pharma A/S 2020-05-14
LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate 2020-04-15
Oneness Biotech receives an upfront payment of US$4M from a global pharma company. 2020-02-25
Oneness Biotech, jointly with affiliate company, Microbio (Shanghai), signs a collaboration memorandum with global pharma company. 2020-02-11
Oneness Biotech has been invited for oral presentation at the 38th Healthcare Conference organized by J.P. Morgan 2020-01-03


Copyright © Oneness Biotech Co., Ltd. All Rights Reserved.